face
lack
specif
antivir
treatment
necessari
develop
new
mean
prevent
case
coronavirida
famili
recogn
includ
potent
human
pathogen
caus
upper
lower
respiratori
tract
infect
well
nosocomi
one
within
purpos
develop
new
antisept
molecul
antisept
virucid
activ
two
calix
aren
deriv
tetraparasulfonatocalix
aren
c
bithiazolyl
tetraparasulfonatocalix
aren
c
sbtz
evalu
toward
human
coronaviru
hcov
compar
result
obtain
previous
chlorhexidin
hexamidin
two
calixaren
show
cytotox
contrari
chlorhexidin
hexamidin
ii
c
show
hexamidin
weak
activ
hcov
iii
c
sbtz
show
stronger
activ
chlorhexidin
ie
log
reduct
viral
titer
min
contact
mol
l
solut
c
sbtz
chlorhexidin
respect
thu
c
sbtz
appear
promis
virucid
antisept
molecul
elsevi
bv
right
reserv
lack
specif
antivir
treatment
still
persist
consid
larg
varieti
virus
alreadi
circul
among
human
popul
potenti
emerg
one
coronavirida
famili
illustr
problem
inde
specif
treatment
avail
fight
coronavirus
infect
known
respons
upper
lower
tract
infect
well
nosocomi
one
thu
effici
mean
prevent
adapt
antisepsisdisinfect
atsd
develop
prevent
environment
spread
infect
human
coronavirus
hcov
histor
known
respons
common
cold
upper
respiratori
tract
infect
larson
et
al
hcov
known
strain
strain
seriou
outbreak
due
newli
discov
hcov
sarscov
ksiazek
et
al
peiri
et
al
reinforc
interest
coronavirida
famili
inde
coronavirus
sinc
involv
seriou
respiratori
diseas
ie
bronchiti
bronchiol
pneumonia
especi
young
children
neonat
gagneur
et
al
gerna
et
al
elderli
peopl
falsey
et
al
immunosuppress
patient
gerna
et
al
pene
et
al
furthermor
shown
surviv
least
sever
hour
differ
environment
condit
ijaz
et
al
lai
et
al
rabenau
et
al
sizun
et
al
final
adapt
properti
abil
speci
barrier
cross
involv
signific
possibl
new
coronavirus
emerg
laud
et
al
li
et
al
vijgen
et
al
thu
specif
ie
pathogen
potenti
environment
resist
evolutionari
abil
make
coronavirida
famili
pertin
model
studi
atsd
activ
new
antivir
molecul
urgent
need
within
purpos
macrocycl
compound
belong
calixaren
famili
de
et
al
rodik
et
al
alreadi
shown
interest
antihiv
antihsv
agent
coveney
costello
harri
harri
hwang
et
al
kral
et
al
motornaya
et
al
field
team
describ
antivir
properti
variou
deriv
bithiazolyl
tetraparasulfonatocalix
evalu
properti
protocol
describ
elsewher
geller
et
al
implement
respond
gener
imper
european
standard
exist
nf
en
evalu
atsd
antivir
activ
human
medicin
afnor
accord
standard
product
induc
log
reduct
viral
titer
qualiti
atsd
antivir
activ
comparison
american
standard
recommend
reduct
log
effici
criterion
astm
astm
gener
principl
protocol
incub
virus
test
product
room
temperatur
defin
contact
time
ii
neutral
product
activ
iii
estim
loss
viral
titer
neutral
process
allow
stop
potenti
antivir
activ
product
ii
remov
eventu
cytotox
iii
prevent
interfer
due
test
viral
infect
achiev
thank
gel
filtrat
method
use
sephadex
tm
column
develop
valid
previous
geller
et
al
assay
requir
appropri
control
especi
check
non
retent
virus
sephadex
tm
column
absenc
interfer
viral
infect
effici
neutral
absenc
cytotox
supp
data
recommend
european
standard
nf
en
control
valid
differ
viral
titer
without
treatment
less
log
afnor
molecular
mass
c
c
sbtz
g
mol
g
mol
respect
thu
suscept
retain
sephadex
tm
column
assess
non
cytotox
filtrat
cytotox
assay
spectrophotometr
measur
conduct
two
concentr
molecul
test
ie
mol
l
mtt
methylthiazol
tetrazolium
nr
neutral
red
assay
first
perform
evalu
cytotox
c
c
sbtz
cell
molecul
ic
inhibitori
concentr
cc
cytotox
concentr
higher
mol
l
even
h
time
requir
obtain
hcov
cytopathogen
effect
assay
perform
filtrat
obtain
filtrat
molecul
sephadex
tm
column
cytotox
also
higher
mol
l
even
h
incub
spectrophotometr
analys
coupl
regress
analys
allow
determin
specif
paramet
molecul
supp
data
retent
rate
sephadex
tm
column
estim
evalu
residu
concentr
filtrat
retent
rate
c
solut
sephadex
tm
column
solut
mol
l
mol
l
respect
lower
retent
rate
mol
l
solut
due
calcul
limit
retent
rate
solut
mol
l
consid
signific
case
c
sbtz
retent
rate
solut
mol
l
respect
supp
data
atsd
antivir
assay
conduct
experi
perform
triplic
valid
test
control
mention
done
time
result
shown
molecul
tabl
c
test
concentr
mol
l
contact
time
min
min
weak
activ
hcov
ie
log
reduct
contact
time
min
min
respect
experi
perform
c
fig
result
obtain
c
sbtz
markedli
better
inde
concentr
mol
l
induc
log
reduct
contact
time
min
respect
mol
l
induc
reduct
log
viral
titer
contact
time
fig
previou
experi
conduct
two
larg
use
antisept
human
medicin
hexamidin
hxm
chlorhexidin
chx
geller
et
al
first
molecul
show
cytotox
toward
cell
inde
chx
show
ic
cc
valu
mol
l
respect
h
way
ic
cc
hxm
mol
l
h
contact
time
thu
first
interest
two
calix
aren
absenc
cytotox
mol
l
h
contrari
hxm
chx
hxm
manner
c
show
weak
activ
hcov
ie
log
reduct
contact
time
min
min
respect
chx
show
better
activ
sinc
induc
log
reduct
mol
l
contact
time
min
respect
log
reduct
mol
l
contact
time
fig
compar
c
sbtz
chx
activ
first
import
point
even
show
certain
antihcov
activ
reach
threshold
fix
european
american
standard
except
chx
mol
l
min
contact
time
howev
contact
time
could
consid
realli
repres
time
atsd
field
condit
thu
realli
attract
characterist
c
sbtz
fast
action
mol
l
soon
min
compar
chx
appear
concentrationand
timedepend
furthermor
activ
persist
min
contact
time
sever
item
yet
taken
consider
analyz
result
first
differ
molecul
test
alon
ie
without
addit
alcohol
without
interf
substanc
way
anticoronaviru
activ
could
estim
realli
repres
field
condit
sinc
virus
normal
found
embed
organ
materi
prevent
action
atsd
result
consist
previou
studi
show
chx
atsd
anticoronaviru
activ
unless
associ
cetrimid
vv
ethanol
sattar
et
al
would
interest
associ
fast
persist
action
c
sbtz
alcohol
solut
inde
even
ethanol
show
good
atsd
activ
particular
coronavirus
rabenau
et
al
sattar
et
al
volatil
natur
involv
transient
action
could
potenti
improv
c
sbtz
activ
furthermor
absenc
cytotox
made
c
sbtz
even
promis
consid
toxic
risk
involv
current
use
atsd
skin
reaction
allergi
occup
diseas
